Bifogade filer
PDF
Beskrivning
| Land | Norge |
|---|---|
| Lista | 12 |
| Sektor | Hälsovård |
| Industri | Bioteknik |
OSLO, NORWAY - 20 May 2025: Genetic Analysis AS ("GA" or "the Company") announces that members of the Board and Management have been allocated GEAN shares in connection with the directed issue approved by the Company's annual general meeting yesterday.
In connection with the directed issue of new shares in the Company with gross proceeds of approximately NOK 12.8 million (the "Directed Issue") approved by the Company's annual general meeting yesterday, 19 May 2025, the following persons discharging managerial responsibilities and their close associates, including members of the Board of Directors and management of the Company, have been allocated shares:
Morten Jurs, Chairperson of the Board in Genetic Analysis AS, has through his controlled company Jurs AS yesterday been allocated 348,837 GEAN-shares at a price of 0.86 NOK per share. Jurs AS owns 348,837 shares in Genetic Analysis AS following the transaction.
Ove Öhman, Board member in Genetic Analysis AS, has through his controlled company Meja AB yesterday been allocated 575,000 GEAN-shares at a price of 0.86 NOK per share. Meje AB owns 575,000 shares in Genetic-Analysis AB following the transaction.
Rune Sørum, Board member in Genetic Analysis AS, has through his controlled company Tind AS yesterday been allocated 250,000 GEAN-shares at a price of 0.86 NOK per share. Tind AS owns 250,000 shares in Genetic-Analysis AB following the transaction. Rune Sørum also have 70,000 options in Genetic-Analysis AS following the transaction.
Thorvald Steen, Board member in Genetic Analysis AS, has through his controlled company Kagge AS yesterday been allocated 930,250 GEAN-shares at a price of 0.86 NOK per share. Thorvald Steen, including Kagge AS owns 2,329,617 shares in Genetic-Analysis AB following the transaction.
Ronny Hermansen, CEO in Genetic Analysis AS, has through the fully owned company InVitroDia AS yesterday been allocated 350,000 GEAN-shares at a price of 0.86 NOK per share. Ronny Hermansen including controlled company owns 1,463,600 shares and 716,667 options following the transaction.
Christina Casén, SVP Medical & Clinical Affairs in Genetic Analysis AS, has yesterday been allocated 348,837 GEAN-shares at a price of 0.86 NOK per share. Christina Casén owns 580,154 shares and 359,997 options following the transaction.
Lars Tiller, Head of Operations in Genetic Analysis AS, has yesterday been allocated 23,256 GEAN-shares at a price of 0.86 NOK per share. Lars Tiller owns 116,747 shares and 210,000 options following the transaction.
Kari Furu, Head of Product and Business Development in Genetic Analysis AS, has yesterday been allocated 34,884 GEAN-shares at a price of 0.86 NOK per share. Kari Furu owns 108,175 shares and 276,667 options following the transaction.
Tore Grøttum, Interim CFO in Genetic Analysis AS, has yesterday been allocated 600,000 GEAN-shares at a price of 0.86 NOK per share. Tore Grøttum owns 1,634,840 shares following the transaction.